Lymphotec Inc.

Tadatoshi Takayama

Teruaki Sekine

Activated lymphocytes are administered to a cancer patient at least five or more times within eight months after performing surgical and chemotherapeutic treatment or radiotherapy for treating cancer particularly liver cancer, so that recurrence of the cancer can be prevented over a long period of five or more years. The activated lymphocytes to be administered while performing treatment of cancer may be autologously derived from a cancer patient or collected from the other cancer patient at need. The activated lymphocytes can be cultivated for proliferating or activating lymphocyte cells collected in the presence of solid-phase anti-CD3 antigen and interleukin 2.

Growing community of inventors

Suginami-ku, Japan

Tadatoshi Takayama